The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

Jean E. Abraham (), Karen Pinilla, Alimu Dayimu, Louise Grybowicz, Nikolaos Demiris, Caron Harvey, Lynsey M. Drewett, Rebecca Lucey, Alexander Fulton, Anne N. Roberts, Joanna R. Worley, Anita Chhabra, Wendi Qian, Anne-Laure Vallier, Richard M. Hardy, Steve Chan, Tamas Hickish, Devashish Tripathi, Ramachandran Venkitaraman, Mojca Persic, Shahzeena Aslam, Daniel Glassman, Sanjay Raj, Annabel Borley, Jeremy P. Braybrooke, Stephanie Sutherland, Emma Staples, Lucy C. Scott, Mark Davies, Cheryl A. Palmer, Margaret Moody, Mark J. Churn, Jacqueline C. Newby, Mukesh B. Mukesh, Amitabha Chakrabarti, Rebecca R. Roylance, Philip C. Schouten, Nicola C. Levitt, Karen McAdam, Anne C. Armstrong, Ellen R. Copson, Emma McMurtry, Marc Tischkowitz, Elena Provenzano and Helena M. Earl
Additional contact information
Jean E. Abraham: University of Cambridge
Karen Pinilla: University of Cambridge
Alimu Dayimu: University of Cambridge
Louise Grybowicz: Cambridge University Hospitals NHS Foundation Trust
Nikolaos Demiris: Athens University of Economics and Business
Caron Harvey: Cambridge University Hospitals NHS Foundation Trust
Lynsey M. Drewett: Royal Devon University Healthcare NHS Foundation Trust
Rebecca Lucey: University of Cambridge
Alexander Fulton: University of Cambridge
Anne N. Roberts: Cambridge University Hospitals NHS Foundation Trust
Joanna R. Worley: University of Cambridge
Anita Chhabra: Cambridge University Hospitals NHS Foundation Trust
Wendi Qian: Cambridge University Hospitals NHS Foundation Trust
Anne-Laure Vallier: Cambridge University Hospitals NHS Foundation Trust
Richard M. Hardy: Cambridge University Hospitals NHS Foundation Trust
Steve Chan: Nottingham University Hospitals NHS Trust
Tamas Hickish: Royal Bournemouth General Hospital
Devashish Tripathi: Royal Wolverhampton NHS Trust
Ramachandran Venkitaraman: East Suffolk and North Essex NHS Foundation Trust
Mojca Persic: University Hospital of Derby and Burton
Shahzeena Aslam: Bedfordshire Hospitals NHS Foundation Trust
Daniel Glassman: Mid Yorkshire Teaching NHS Trust
Sanjay Raj: University Hospital Southampton NHS Foundation Trust
Annabel Borley: Velindre Cancer Centre
Jeremy P. Braybrooke: University Hospitals Bristol and Weston NHS Foundation Trust
Stephanie Sutherland: Mount Vernon Cancer Centre
Emma Staples: Barking, Havering and Redbridge University Hospitals NHS Trust
Lucy C. Scott: Beatson West Of Scotland Cancer Centre
Mark Davies: Swansea Bay University Health Board
Cheryl A. Palmer: North West Anglia NHS Foundation Trust
Margaret Moody: West Suffolk Hospital NHS Foundation Trust
Mark J. Churn: Worcestershire Acute Hospitals NHS Trust
Jacqueline C. Newby: Royal Free London NHS Foundation Trust
Mukesh B. Mukesh: East Suffolk & North Essex NHS Trust
Amitabha Chakrabarti: University Hospitals Dorset NHS Foundation Trust
Rebecca R. Roylance: University College London Hospitals NHS Foundation Trust
Philip C. Schouten: Cambridge University Hospitals NHS Foundation Trust
Nicola C. Levitt: Oxford University Hospital NHS Foundation Trust
Karen McAdam: North West Anglia NHS Foundation Trust
Anne C. Armstrong: The Christie NHS Foundation Trust and Division of Cancer Sciences
Ellen R. Copson: University of Southampton
Emma McMurtry: Sale
Marc Tischkowitz: University of Cambridge
Elena Provenzano: Cambridge University Hospitals NHS Foundation Trust
Helena M. Earl: University of Cambridge

Nature, 2024, vol. 629, issue 8014, 1142-1148

Abstract: Abstract PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer1,2, who were germline BRCA1 and BRCA2 wild type3. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin–paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)4, and secondary end points included event-free survival (EFS) and overall survival (OS)5. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (P = 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank P > 0.9), respectively; OS was 90% and 87.2% (log-rank P = 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank P

Date: 2024
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41586-024-07384-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:629:y:2024:i:8014:d:10.1038_s41586-024-07384-2

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-024-07384-2

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().